Trenbolone Acetate
Tren A · Fina
Short-acting 19-nor ester requiring every-other-day dosing. Simple model — peak calibrated.
Overview
Trenbolone acetate is the short-acting acetate ester of trenbolone, the potent 19-nor androgen originally formulated as Finaplix for cattle. It binds the androgen receptor at roughly three times testosterone's affinity, drives nitrogen retention and protein synthesis aggressively, and does not aromatize or undergo 5-alpha-reduction. Its 1.5-day half-life (36 hours) is the defining feature: serum levels swing fast, so research protocols have used every-other-day or daily injection to hold levels flat. The short ester also means faster clearance if side effects appear. Harm-reduction priorities mirror the enanthate version (blood pressure, lipids, kidney markers, psychological effects) plus a distinct acute injection cough reported post-injection. Hepatotoxicity is rated mild and HPTA suppression is severe and rapid.
Pharmacokinetic summary
- Model tier
- Simple (t½ + F, Tmax estimated)
- Half-life
- 2 days
- Cmax
- 68.9 ng/dL
- Bioavailability
- 87%
- Typical dose
- 35–100 mg
Harm reduction
- Aromatizes
- No
- DHT derivative
- No
- Hepatotoxicity
- mild
- Injection frequency
- EOD–daily
⚠ Trenbolone + PDE5 inhibitors (e.g. tadalafil) raises risk of cardiovascular strain.
Related compounds
Trenbolone Enanthate
Long-acting 19-nor injectable; potent androgen with no aromatization. Simple model — peak calibrated.
Trenbolone Hexahydrobenzylcarbonate
Long-acting trenbolone (original Parabolan). Simple model — peak calibrated.
Testosterone Enanthate
Long-acting testosterone ester; the most common TRT and cycle base. Reaches steady state in ~5 weeks.
Protocols featuring Trenbolone Acetate
Comments
Loading comments…